RESEARCH STANDARD OPERATING PROCEDURES (SOP)
Controlled Substances Utilized in Clinical Research

1. PURPOSE: To establish a standard operating procedure for the research pharmacy’s handling of controlled substances utilized in clinical research at the South Texas Veterans Health Care System (STVHCS).

2. POLICY:
   a. Definitions
      (1) Compounded preparations: Any alteration in the packaging or dosage form of a commercially supplied medication (i.e. bulk to unit dose preparation or ampules to diluted syringes).

3. ACTION:
   a. Procedures
      (1) Ordering
         (a) When investigational controlled substances are not supplied by the study sponsor, the Research Pharmacist, with the concurrence of the ACOS for Research, will place a request to the Pharmacy Procurement Supervisor for the purchase of a controlled substance to be utilized in clinical research pursuant to a principal investigator’s study protocol.

         (b) The Chief of Pharmacy will initiate the order of all purchase requests through the Pharmacy Procurement Supervisor.

      (2) Opening Shipments, Receiving and Verification of Posting in VistA
         (a) All controlled substances being tested or evaluated in study protocols will be received by the Pharmacy Procurement Supervisor as authorized by the Chief of Pharmacy.

         (b) The source of controlled substances may be from a prime vendor, a non-prime vendor, or directly from a study sponsor. In all instances, pharmacy procurement personnel or designee will receive, open, count the contents of the shipment, and sign and date the invoice or packing/shipping documentation for that shipment in the presence of the Accountable Officer (AO).

         In the instance of a prime vendor receipt, pharmacy procurement personnel or designee will process the received items in the drug accountability package in VistA, and Research Pharmacist will verify the invoice in the drug accountability package in VistA and perform an invoice review in Receipts into Pharmacy in the Controlled Substances package in VistA. The Research Pharmacist will print the invoice review and sign with a witness.
RESEARCH SERVICE POLICY MEMORANDUM 11-63

2. In the instance of a non-prime vendor receipt, pharmacy procurement personnel or designee will receive the controlled substances as described above (excluding the drug accountability package invoice processing), and the Research Pharmacist will receive the Purchase Order Number in the Receipts into Pharmacy option of the Controlled Substance package in VistA. Then the Research Pharmacist will perform a Purchase Order Review in Receipts into Pharmacy menu in the Controlled Substances package in VistA. The Research Pharmacist will print the purchase order history and sign with a witness.

3. In the instance of a controlled substance receipt directly from a Study Sponsor, pharmacy procurement personnel will receive the controlled substances as described above (excluding the drug accountability package invoice processing), and the Research Pharmacist will perform a Balance Adjustment entry using the Supervisor menu in the Controlled Substances package in VistA. The balance adjustment will cite the source and the invoice or packing/shipping documentation number of the received items in the comments field. The Research Pharmacist will print the balance adjustment sheet and sign with a witness.

(3) Inventory

(a) Perpetual inventory of controlled substances stored and dispensed by the research pharmacist will be maintained and inspected monthly pursuant to VHA Handbook 1108.1.

(b) The research pharmacist will inventory the research vault with an accompanying pharmacist on Tuesdays and Fridays via the inventory sheet generated using the controlled substance menu in the VistA electronic system. This inventory sheet will be filed in the research pharmacy and provided to the appointed controlled substance inspecting officer monthly in accordance with VHA Handbook 1108.1.

(c) Although the research vault is a commercial Automated Dispensing System (ADS), the Research Vault is not subject to the same procedures and requirements of ADS on nursing units as detailed under Pharmacy Service Policy Memorandum Automated Dispensing System Policy for Pharmacy Omnicell Machines as its function is only as a vault.

(4) Preparation and Dispensing

(a) If controlled substances within the research vault require compounding prior to dispensing to an inpatient ward, patient, agent of a patient or study personnel, the following procedure will be followed:
1. An order or prescription for the compounded drug (dispensing item) must be received.

   a. Schedule II substances to be provided for inpatient services will be electronically ordered in CPRS for a period not to exceed 7 days in accordance with local pharmacy policy.

   b. All outpatient prescriptions for schedule II substances must also be written on VA Form 10-2577f. The form must be completed in accordance with local pharmacy policy.

   c. Schedule III thru V prescriptions for both inpatient wards and outpatients will be electronically ordered in CPRS in accordance with local pharmacy policy.

2. At the time of compounding, the Research Pharmacist will remove the bulk drug (orderable drug) from the research vault assigning it to the compounded drug (dispensing drug) (i.e. zzINV-ABC-Compounded Drug A 10mg).

3. Balance adjustments from the bulk drug (orderable drug) will be made by the Research Pharmacist in the VistA controlled substances package as described below:

   a. The number of units of the bulk drug removed from the vault to be used to prepare the compounded drug should be deducted from the inventory balance in the form of a balance adjustment in the VistA controlled substances package.

   b. If there is any waste in production of the compounded drug, it is to be documented within the balance adjustment comment field citing the following for justification: patient identifying information (i.e. initial of patient’s last name and last four of social security number), dose and units that were prepared, amount lost to waste, and initials of witnessing pharmacist or technician or technician to the waste.

   c. A balance adjustment sheet documenting the compounding and the waste will be generated in VistA and signed by the research pharmacist as well as a witnessing pharmacist or technician or technician. This balance adjustment sheet will be filed in the research pharmacy. These sheets and a balance adjustment report will be provided to the appointed controlled substance inspecting officer as well as a pharmacy designee on a monthly basis.

4. Balance adjustments to the compounded drug (dispensing drug) will be made in VistA as described below:
RESEARCH SERVICE POLICY MEMORANDUM 11-63

a. The number of units of the compounded drug produced will be added to the inventory balance in the form of another balance adjustment using the VistA controlled substances package.

b. The compounded drug must be stocked in the research vault using the compounded drug entry (dispensing drug) (i.e. zzINV-ABC-Compounded Drug A 10mg).

c. When the compounded drug will be dispensed to the inpatient ward’s Omnicell, the research pharmacist will remove the compounded drug from the research vault assigning it to the respective inpatient ward entry (i.e. zz_NAOU_7A).

d. When the compounded drug will be dispensed to the patient as an outpatient prescription following a medication order entry in VistA, the research pharmacist will remove the compounded drug from the research vault assigning it to the specific patient.

e. The compounded drug will be dispensed to the inpatient ward Omnicell or to the patient in the same number of units that were added into the inventory balance for that compounded drug in VistA. The resulting inventory balance after dispensing will be zero.

f. A VistA generated balance adjustment report will be provided to the appointed controlled substance inspecting officer as well as to a pharmacy designee on a monthly basis.

5. INPATIENT DISPENSING AND ADMINISTRATION PROCEDURE

a. The procedure for dispensing the compounded drug to an inpatient ward is described below:

   (1) The research pharmacist will dispense the product to the ward on VA Form 10-2321, prepared in duplicate, and physically stock this medication into the Omnicell in the appropriate drawer specified for that compounded drug. VA Form 10-2321 will document the quantities received, date, and serial number and will be signed by the research pharmacist and receiving nurse, charge nurse or nurse manager. All VA Form 10-2321 will be filed in the research pharmacy.

b. The procedure for administration of the drug dispensed to the ward is described below:

   (1) The nurse will remove the compounded drug from the Omnicell, assigning it to the patient to which it will be given. Only in the case
of computer failure will manual forms be utilized for dispensing to the patient. In such an instance, VA Form 10-2638 will be utilized as a controlled substance administration record. Expended VA Form 10-2638 will be returned to the research pharmacy, and the research pharmacist must review the completed form for errors, losses and/or waste upon receipt from the nurse prior to filing.

(2) If there is any waste during the administration process, the nurse will verify at the prompting of the Omnicell the amount of waste, by whom and the corresponding witness. Each nurse will provide an electronic signature upon verification.

6. OUTPATIENT DISPENSING PROCEDURE

a. The procedure for dispensing the compounded drug to a patient, agent of a patient or study personnel as an outpatient medication is described below:

(1) The compounded drug will be dispensed by the research pharmacist in accordance with local pharmacy policy.

(2) All persons picking up completed controlled substance prescriptions will sign the prescription pick-up label to be maintained in the research pharmacy.

(b) If the controlled substance within the research vault does not require compounding prior to dispensing, the following procedure will be followed:

1. An appropriate order or prescription must first be received prior to dispensing to an inpatient ward, patient, agent of patient or study personnel. All orders and prescriptions must be in accordance with local pharmacy policy.

2. When the drug will be dispensed to an inpatient ward Omnicell, the research pharmacist will remove the drug from the research vault assigning it to the respective inpatient ward (i.e. zz_NAOU_7A).

3. When the drug will be dispensed to the patient, agent of the patient or study personnel as an outpatient prescription, the research pharmacist will remove the drug from the research vault assigning it to the patient.

4. The procedure for dispensing to a ward Omnicell and administration of the drug detailed under INPATIENT DISPENSING AND ADMINISTRATION PROCEDURE (1.e.1.e) is applicable and will be followed accordingly.

5. The procedure for dispensing the drug to the patient as an outpatient prescription detailed under OUTPATIENT DISPENSING (1.e.1.f) is applicable and will be followed accordingly.
(5) Discrepancy Monitoring

(a) The research pharmacist will follow Pharmacy Service Policy for reconciliation of controlled substances when dispensing from the research vault to automated dispensing machines.

(6) Final Disposition

(a) Any unused controlled substances utilized in clinical research and stored within an inpatient ward’s Omnicell that are determined to be unusable will be returned to the research pharmacy. They will be held for disposal in accordance with local pharmacy policy or for return to the study sponsor as described in the procedure below:

1. The research pharmacist will work with the charge nurse or nurse manager to initiate and complete the transfer no later than the next day, excluding weekends and holidays, after the patient will no longer receive the medication.

2. The research pharmacist will perform a destock of the medication in the Omnicell citing the reason for destock as *drug not administered to patient – held for disposal*. The Omnicell will prompt for an electronic signature from the individual performing the destock as well as a witness to the destock.

3. If the medications are to be disposed in accordance with the local pharmacy policy, an entry must be posted in the controlled substance destruction menu in VistA. The controlled substances will be placed in sealed bags and labeled in accordance with local policy. The appointed controlled substance inspecting officer must verify the “Drugs on Hold for Destruction” report in VistA and the accountability of the sealed bags of the unusable controlled substances monthly. The contents will also be verified at the time of disposal. The unusable controlled substances ledger must be “cleared” of inventory accountability in VistA once the disposal of an item has been rendered.

4. The research pharmacist will utilize the local pharmacy policy for guidance on appropriate disposition. Those items disposed of will be documented on a drug specific electronic drug accountability record to include: drug name, dosage form, strength, quantity, and date of disposal.

5. If the medications are to be held for pharmaceutical company disposition, the company will be notified of medications awaiting return, and the medications will be stored in the research pharmacy until the pharmaceutical company resumes custody. All inventory and storage policies described above are applicable and will be followed accordingly. Schedule II drugs will be returned to the study sponsor utilizing DEA Form 222 to be completed by the sponsor.
(b) Any unused controlled substances utilized in clinical research and stored in an inpatient ward Omnicell determined reusable will be returned to the research pharmacy. If determined reusable, the medications can be returned to the research pharmacy inventory as described in the procedure below:

1. The research pharmacist will work with the charge nurse or nurse manager to initiate and complete the transfer back no later than the next day, excluding weekends and holidays, after the patient will no longer receive the medication.

2. The research pharmacist will perform a Destock of the Omnicell citing the reason for destock as *drug not administered to patient - return to stock*. The Omnicell will prompt for an electronic signature from the individual performing the destock as well as a witness to the destock.

3. The research pharmacist will restock the research vault with the respective controlled substance. The research vault will prompt for an electronic signature from the individual performing the restock as well as a witness to the restock.

4. The research pharmacist will then balance adjust the inventory for that controlled substance in VistA to reflect the quantity to be returned to stock.

5. Within the balance adjustment comment field, the following should be cited as justification: date, patient identifying information (i.e. Initial of patient's last name and last four of patient's social security number), reason for return of the investigational controlled substance, serial number and the initials of the witnessing pharmacist or technician to return to stock. A balance adjustment sheet will be generated in VistA and signed by the research pharmacist as well as a witnessing pharmacist or technician. This balance adjustment sheet will be filed in the research pharmacy. These sheets and a balance adjustment report will be provided to the appointed controlled substance inspecting officer as well as a pharmacy designee on a monthly basis.


5. RESPONSIBILITY: ACOS for Research and Development (151) and Chief, Pharmacy Service (119)


7. RECERTIFICATION: October 2016
RESEARCH SERVICE POLICY MEMORANDUM 11-63

KIMBERLY K. SUMMERS, PHARM.D.
Acting ACOS for Research and Development

DAVID RACETTE, RPH
Chief, Pharmacy Service